NSTL国家科技图书文献中心

1. Quantitative Benefit-Risk Assessment of Vaccination Against COVID-19: A Systematic Review NSTL国家科技图书文献中心

Newbern, E. Claire | Wildisen, Lea ... - 《Pharmacoepidemiology and drug safety》 - 2025,34(2) - e70099～e70099 - 共14页

摘要： benefit-risk assessments (qBRAs). Prior work on other | assessment of COVID-19 vaccine qBRAs together with | PurposeWith the introduction of COVID-19 | vaccines, there has been a proliferation of quantitative | types of vaccines has found that published qBRAs have

关键词： COVID-19 | quantitative benefit-risk assessment | vaccination | COVID‐19 | quantitative benefit–risk assessment

2. Cost – benefit analysis through stochastic risk assessment on mining waste management considering the circular economy’s requirements NSTL国家科技图书文献中心

Evangelos Machairas | Emmanouil A. Varouch...... - 《Journal of cleaner production》 - 2025,489(Jan.15) - 144388.1～144388.23 - 共23页

摘要： Stochastic Risk* Analysis- Assessment (SRA) to provide a* | Applied Engineering through Cost Benefit | Analysis and Bayesian Analysis of Stochastic Risk | Assessment for Mining Waste Management contributes | -compliance with the corresponding legislation. Cost benefit

关键词： Mining waste management in industrial scale | Cost benefit analysis | Risk assessment | Applied engineering | Metal recovery | Optimal decision | Reduce-recover-reuse wastes | Environmental safety | Implementation of CBA | Bayesian analysis...

3. Development of a novel tool for individual treatment trials in mucopolysaccharidosis NSTL国家科技图书文献中心

Wiesinger, Anna-Mari... | Bigger, Brian ... - 《Journal of inherited metabolic disease》 - 2025,48(1) - e12816～e12816 - 共14页

摘要：) quantitative risk-benefit* assessment (RBA) of selected* | evaluation of drug effects by implementing a risk-benefit | Mucopolysaccharidosis (MPS) encompasses a | group of genetic lysosomal storage disorders, linked | to reduced life expectancy and a significant lack

关键词： decision analysis framework | immunomodulation | individual treatment trials | mucopolysaccharidosis | personalized medicine | repurposing | risk-benefit assessment | risk–benefit assessment

4. Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study NSTL国家科技图书文献中心

Gisbert, Javier P. | Schreiber, Stefan ... - 《Inflammatory bowel diseases》 - 2025,31(5) - 1281～1294 - 共14页

摘要： benefit-risk assessment suggested patients are | profiles. Patient choices in the benefit-risk assessment | -centric benefit-risk* assessment suggested 200 mg of* | quantified the benefit-risk* trade-offs that patients were* | risks were generated. A patient-centric benefit-risk

关键词： benefit-risk assessment | filgotinib | ulcerative colitis

5. ESR Essentials: basic physics of MR safety-practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology NSTL国家科技图书文献中心

Nordin, Love Engstro... | Aberg, Karin ... - 《European radiology.》 - 2025,35(2) - 572～579 - 共8页

摘要： principles described can be applied to the risk assessment | hazard, loud noise, and the risk* of heating. Safe use* | for how each risk* can be minimized or* | ObjectivesThe use of magnetic resonance | imaging (MRI) is safe from a long-term perspective since

关键词： Magnetic resonance imaging | Static magnetic field | Radiofrequency field | Time-varying magnetic field gradients | Risk-benefit assessment

6. A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector NSTL国家科技图书文献中心

Link E.K. | Tscherne A.... - 《Vaccine》 - 2025,43P1 - 126521～126521 - 共19页

摘要： Benefit-Risk Assessment of VAccines by TechnolOgy | © 2024 The AuthorsThe Brighton Collaboration | (BRAVATO) was formed to evaluate the safety and other key | features of new platform technology vaccines. This | manuscript provides an overview of Modified Vaccinia virus

关键词： Benefit/risk | Modified vaccinia virus Ankara | Safety | Vaccine | Virus

7. Orthodontic treatment protocol versus Peer Assessment Rating: Assessing the quality of orthodontic treatment NSTL国家科技图书文献中心

Shelswell, Jonathan ... | Kelly, Brian M.... - 《Journal of orthodontics》 - 2025,52(1) - 45～55 - 共11页

摘要：Objective: To apply the Peer Assessment* Rating* | assessment with weighted (W) and unweighted (U) PAR | critical outcome assessment* than PAR, identifying* | (PAR) to cases that have been assessed by the NHS | Business Service Authority (NHSBSA) using the orthodontic

关键词： epidemiology in orthodontics (including occlusal indices) | health services and quality of life aspects | economics of orthodontic delivery systems | risk/benefit assessment

8. Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023 NSTL国家科技图书文献中心

Matteo Guerra | Emily Alouani ... - 《European Journal of Haematology》 - 2025,114(1) - 89～97 - 共9页

摘要： therapeutic response rates, acceptable risk/benefit* ratio* | assessment of toxicity to an adaptive approach based on | ABSTRACT Background Early‐phases clinical | trials (Phases 1 and 2) have evolved from a traditional | patients' medical needs and access to effective new

关键词： benefit risk assessment | clinical protocols | clinical trial | hematological malignancies | Phase 1 | survival analysis

9. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment NSTL国家科技图书文献中心

Vass, Caroline | Pinto, Cathy Anne ... - 《Future oncology》 - 2025,21(6/7) - 833～842 - 共10页

摘要： therapies for a high-risk* patient who had recently* | median disease-free survival and reduced risk* of side* | to a typical high-risk* postnephrectomy RCC patient.* | IntroductionTo quantify physicians | ' preferences for adjuvant renal cell carcinoma (RCC

关键词： Renal cell carcinoma | preferences | shared decision-making | discrete-choice experiment | benefit-risk assessment

10. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment NSTL国家科技图书文献中心

Calhoun, Shawna R. | Vass, Caroline ... - 《Future oncology》 - 2025,21(6/7) - 843～851 - 共9页

摘要：IntroductionTo quantify patients' preferences | for adjuvant renal cell carcinoma (RCC | ) treatments.Patients and MethodsPreferences were elicited using a | discrete-choice experiment requiring RCC patients to | choose between 2 hypothetical treatments. Data were

摘要： benefit-risk assessments (qBRAs). Prior work on other | assessment of COVID-19 vaccine qBRAs together with | PurposeWith the introduction of COVID-19 | vaccines, there has been a proliferation of quantitative | types of vaccines has found that published qBRAs have

关键词： COVID-19 | quantitative benefit-risk assessment | vaccination | COVID‐19 | quantitative benefit–risk assessment

摘要： Stochastic Risk Analysis- Assessment (SRA) to provide a | Applied Engineering through Cost Benefit | Analysis and Bayesian Analysis of Stochastic Risk | Assessment for Mining Waste Management contributes | -compliance with the corresponding legislation. Cost benefit

关键词： Mining waste management in industrial scale | Cost benefit analysis | Risk assessment | Applied engineering | Metal recovery | Optimal decision | Reduce-recover-reuse wastes | Environmental safety | Implementation of CBA | Bayesian analysis...

摘要：) quantitative risk-benefit assessment (RBA) of selected | evaluation of drug effects by implementing a risk-benefit | Mucopolysaccharidosis (MPS) encompasses a | group of genetic lysosomal storage disorders, linked | to reduced life expectancy and a significant lack

关键词： decision analysis framework | immunomodulation | individual treatment trials | mucopolysaccharidosis | personalized medicine | repurposing | risk-benefit assessment | risk–benefit assessment

摘要： benefit-risk assessment suggested patients are | profiles. Patient choices in the benefit-risk assessment | -centric benefit-risk assessment suggested 200 mg of | quantified the benefit-risk trade-offs that patients were | risks were generated. A patient-centric benefit-risk

关键词： benefit-risk assessment | filgotinib | ulcerative colitis

摘要： principles described can be applied to the risk assessment | hazard, loud noise, and the risk of heating. Safe use | for how each risk can be minimized or | ObjectivesThe use of magnetic resonance | imaging (MRI) is safe from a long-term perspective since

关键词： Magnetic resonance imaging | Static magnetic field | Radiofrequency field | Time-varying magnetic field gradients | Risk-benefit assessment

摘要： Benefit-Risk Assessment of VAccines by TechnolOgy | © 2024 The AuthorsThe Brighton Collaboration | (BRAVATO) was formed to evaluate the safety and other key | features of new platform technology vaccines. This | manuscript provides an overview of Modified Vaccinia virus

关键词： Benefit/risk | Modified vaccinia virus Ankara | Safety | Vaccine | Virus

摘要：Objective: To apply the Peer Assessment Rating | assessment with weighted (W) and unweighted (U) PAR | critical outcome assessment than PAR, identifying | (PAR) to cases that have been assessed by the NHS | Business Service Authority (NHSBSA) using the orthodontic

关键词： epidemiology in orthodontics (including occlusal indices) | health services and quality of life aspects | economics of orthodontic delivery systems | risk/benefit assessment

摘要： therapeutic response rates, acceptable risk/benefit ratio | assessment of toxicity to an adaptive approach based on | ABSTRACT Background Early‐phases clinical | trials (Phases 1 and 2) have evolved from a traditional | patients' medical needs and access to effective new

关键词： benefit risk assessment | clinical protocols | clinical trial | hematological malignancies | Phase 1 | survival analysis

摘要： therapies for a high-risk patient who had recently | median disease-free survival and reduced risk of side | to a typical high-risk postnephrectomy RCC patient. | IntroductionTo quantify physicians | ' preferences for adjuvant renal cell carcinoma (RCC

关键词： Renal cell carcinoma | preferences | shared decision-making | discrete-choice experiment | benefit-risk assessment

摘要：IntroductionTo quantify patients' preferences | for adjuvant renal cell carcinoma (RCC | ) treatments.Patients and MethodsPreferences were elicited using a | discrete-choice experiment requiring RCC patients to | choose between 2 hypothetical treatments. Data were

关键词： Renal cell carcinoma | preferences | shared decision-making | discrete-choice experiment | benefit-risk assessment

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： Stochastic Risk* Analysis- Assessment (SRA) to provide a* | Applied Engineering through Cost Benefit | Analysis and Bayesian Analysis of Stochastic Risk | Assessment for Mining Waste Management contributes | -compliance with the corresponding legislation. Cost benefit

摘要：) quantitative risk-benefit* assessment (RBA) of selected* | evaluation of drug effects by implementing a risk-benefit | Mucopolysaccharidosis (MPS) encompasses a | group of genetic lysosomal storage disorders, linked | to reduced life expectancy and a significant lack

摘要： benefit-risk assessment suggested patients are | profiles. Patient choices in the benefit-risk assessment | -centric benefit-risk* assessment suggested 200 mg of* | quantified the benefit-risk* trade-offs that patients were* | risks were generated. A patient-centric benefit-risk

摘要： principles described can be applied to the risk assessment | hazard, loud noise, and the risk* of heating. Safe use* | for how each risk* can be minimized or* | ObjectivesThe use of magnetic resonance | imaging (MRI) is safe from a long-term perspective since

摘要：Objective: To apply the Peer Assessment* Rating* | assessment with weighted (W) and unweighted (U) PAR | critical outcome assessment* than PAR, identifying* | (PAR) to cases that have been assessed by the NHS | Business Service Authority (NHSBSA) using the orthodontic

摘要： therapeutic response rates, acceptable risk/benefit* ratio* | assessment of toxicity to an adaptive approach based on | ABSTRACT Background Early‐phases clinical | trials (Phases 1 and 2) have evolved from a traditional | patients' medical needs and access to effective new

摘要： therapies for a high-risk* patient who had recently* | median disease-free survival and reduced risk* of side* | to a typical high-risk* postnephrectomy RCC patient.* | IntroductionTo quantify physicians | ' preferences for adjuvant renal cell carcinoma (RCC